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Introduction: Currently available endothelin receptor antagonists for treating pulmonary 
arterial hypertension block either the endothelin (ET) receptor A or both A and B receptors. 
Transition from one endothelin receptor antagonist to another may theoretically alter side-effects 
or efficacy. We report our experience of a transition from sitaxsentan to ambrisentan, both 
predominant ETA receptor antagonists, in pulmonary arterial hypertension patients.
Methods: At Baylor Pulmonary Hypertension Center, 18 patients enrolled in the open-label 
extension phase of the original sitaxsentan studies (Sitaxsentan To Relieve ImpaireD Exercise) 
were transitioned to ambrisentan (from July 2007 to September 2007) at the time of study 
closure. Pre-transition (PreT), 1 month (1Mth) and 1 year (1Yr) post-transition assessments 
of 6-minute walk distance (6MWD), brain naturetic peptide (BNP) levels, WHO functional 
class (WHO FC), Borg dyspnea score (BDS), oxygen saturation, liver function, and peripheral 
edema were compared.
Results: 6MWD was 356 ± 126 m at PreT, 361 ± 125 m at 1Mth, and 394 ± 114 m at 1Yr 
(mean ± SD). There was no difference in the walk distance at 1Mth and 1Yr post transition 
compared with PreT (P = 0.92, 0.41 respectively). Oxygen saturation was no different at 1Mth 
and 1Yr to PreT level (P = 0.49 and P = 0.06 respectively). BNP was 178 ± 244 pg/mL at PreT, 
129 ± 144 pg/mL at 1Mth and 157 ± 201 at 1Yr. Peripheral edema was present in 7/18 patients 
at PreT, in 8/16 patients at 1Mth, and in 6/13 patients at 1Yr post transition. Proportions of 
patients with edema over these 3 time points did not change significantly (P = 0.803). At 1Yr, 
2 patients had died, 1 had undergone lung transplantation, 1 had relocated, and 1 patient was 
started on intravenous prostacyclin therapy. Over 3 points (baseline, 1 month, and 1 year), there 
was no significant change in function class (P = 0.672).
Conclusion: Our limited data suggest that ETA receptor antagonists can be switched from 
one to another with sustained exercise capacity and maintained WHO FC with no increase in 
incidence of peripheral edema.
Keywords: right heart failure, 6-minute walk distance, endothelial receptor antagonist, 
echocardiogram
Introduction
Pulmonary arterial hypertension (PAH) is a progressive disease resulting from 
pulmonary vascular remodeling leading to right heart failure.1 Endothelin 1 (ET-1), 
a modulator of pulmonary vascular remodeling, has an important role in the 
pathophysiology of this disease. ET-1 binds to 2 receptors, ETA and ETB. Endothelin 
receptor antagonists (ETRAs) block either A or A and B receptors are used to treat 
PAH. Two Food and Drug Administration (FDA) -approved ETRAs are available to 
treat PAH in the US. Sitaxsentan, a predominantly ETA receptor antagonist, was studied Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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in the US, Europe, and Canada; sitaxsentan was approved 
in Europe and Canada but did not receive FDA approval 
in the US. Thus patients enrolled in open label sitaxsentan 
extension studies were transitioned to ambrisentan at the 
time of sitaxsentan study closure. We report our single-
center experience of patients transitioning from sitaxsentan 
to ambrisentan after study closure.
To date indications for changing from one ETRA to 
another ETRA are anecdotal. Side effect profiles such as 
liver toxicity and drug interactions differ between these 
ETRAs.2 Due to the predominant blockade of endothelin A 
receptor with sitaxsentan we decided to switch our patients 
from sitaxsentan to ambrisentan (both predominantly ETA 
receptor antagonists). We present the available long-term 
clinical data for 18 patients switched to ambrisentan at the 
time of sitaxsentan study closure.
Method
Eighteen PAH patients were enrolled in the open-label exten-
sion phase of the original sitaxsentan studies (Sitaxsentan 
To Relieve ImpaireD Exercise [STRIDE] −2, −3 and −6) at 
Baylor Pulmonary Hypertension Center. All patients were 
on 100 mg oral daily of sitaxsentan. Patients were enrolled 
in the open label extension phase of clinical studies, which 
permitted addition of other PAH medications as clinically 
indicated. These patients were changed to ambrisentan 
(5 mg oral daily) (between July 2007 and September 2007) 
at the time of study closure. This transition was necessary 
because sitaxsentan did not gain FDA approval in US and 
hence this drug was unavailable to patients after sitaxsentan 
study was closed.
Data was collected for each patient at pre-transition 
(PreT), 1 month (1Mth) (48 ± 28 days, range 19–123), and 
1 year (1Yr) post transition (401 ± 73 days, range 252–489). 
Collected data included 6-minute walk distance (6MWD), 
brain naturetic peptide (BNP) plasma concentrations, WHO 
functional class (WHO FC), Borg dyspnea score (BDS), 
presence of peripheral edema, changes in diuretic dose, and 
liver function tests. Patient 2 was hospitalized at the time of 
transition for acute gastroenteritis and remained in the hos-
pital till he died from worsening right heart failure. Hence 
limited data were available for patient 2. Patient 17 had only 
laboratory testing done at 1Mth and was unable to do the 
walk test at 1Yr due to severe hip pain. Patient 3 was taken 
off ambrisentan and started on intravenous treprostinil due 
to worsening pulmonary hypertension 9 month post transi-
tion and died 13 months post transition. This patient did not 
have a walk test done at 1Yr because of severe back pain, 
which was considered a treprostinil related side-effect by 
the treating physician. Patient 18 progressed to WHO FC 
IV at 1Mth from WHO FC III at baseline and subsequently 
underwent lung transplantation 5.5 months post transition. 
Patient 9 relocated 5 months post transition. Hence, 1Yr data 
available for 13 patients was included in this analysis.
Statistical analysis
All data are reported as mean ± standard deviation (SD) 
unless stated otherwise. Differences between groups were 
determined by using paired Student’s t-test. A chi-square test 
was used to evaluate the significance of change of WHO FC 
over 3 time points. We also used a chi-square test to examine 
the difference in proportions of patients who experienced 
edema at 3 time points. Analyses were conducted using 
SAS (v. 9.2;SAS Institute Inc., Cary, NC). Significance 
was accepted at P , 0.05 and all hypothesis testing was 
two-sided.
Results
Demographic and baseline characteristics are outlined in 
Table 1. There were 15 females and 3 males with a mean 
age of 52 ± 14 (mean ± SD). At 1Mth, the ambrisentan dose 
was increased in 7 patients to 10 mg and 10 patients were 
continued on 5 mg dose. Patient 2 was on ambrisentan 5 mg 
when he died in the hospital. At 1Yr, 8 patients were on 
10 mg dose, 5 patients remained on 5 mg, and 1 patient was 
taken off ambrisentan for worsening disease and started on 
intravenous prostacyclin therapy (patient 3). Patient 11 had 
sildenafil added to ambrisentan 4 months prior to 1Yr. None 
of the patients discontinued ambrisentan due to liver function 
abnormalities (Table 2). Patient 15 had increased aspartate 
aminotransferase at 1Mth (3.5 × upper limit of normal) 
which returned to normal on repeat testing in 1 week without 
interruption in therapy.
6MWD was 356 ± 126 m at PreT, 361 ± 125 m at 1Mth, 
and 394 ± 114 m at 1Yr. There was no difference in the 
6MWD at 1Mth and at 1Yr compared with PreT (P = 0.92 and 
P = 0.41 respectively) (Figure 1). BNP was not significantly 
different at 1Mth and at 1Yr compared with PreT (P = 0.50 
and P = 0.83 respectively) (Figure 2). BDS was 2.5 ± 1.2 
(range 0 to 4) at PreT in 17 patients, 2.4 ± 1.4 (range 0 to 4) 
at 1Mth in 16 patients and 2.6 ± 1.3 (range 0.5 to 5) at 1Yr 
in 12 patients (Figure 3). These values was not significantly 
different (P = 0.88 and 0.81 respectively).
Eleven of the 18 patients were idiopathic PAH (IPAH) 
patients. Patients were divided into 2 groups – IPAH, and PAH 
associated with other conditions, and data was analyzed to Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 1 Demographics and baseline patient characteristics of transitioned patients
Patient  
number
Age, yr Gender Race BMI, kg/m2 PAH etiology PAH medications* Duration of illness 
at transition, yrs
1 50 F c 19.31 iPAH  none 6.3
2 44 M c 21.89 cHD associated PAH Treprostinil, sildenafil 5.4
3 72 M c 20.48 iPAH  Iloprost, sildenafil 3.9
4 54 F c 28.03 cTD associated PAH Sildenafil 4.3
5 42 F c 34.37 iPAH Sildenafil 7.9
6 60 F H 25.24 iPAH Sildenafil 7.4
7 53 F c 36.39 iPAH Sildenafil 3.6
8 32 M c 43.45 iPAH Sildenafil, iloprost 3.3
9 33 F Asian 21.4 cHD associated PAH  iloprost 4.8
10 49 F c 26.73 cTD associated PAH Sildenafil 3.8
11 56 F H 31.17 iPAH none 3.0
12 68 F H 31.95 iPAH Sildenafil 3.4
13 59 F c 24.58 cTD associated PAH none 7.2
14 67 F Asian 23.04 iPAH Sildenafil, Iloprost 4.6
15 45 F Asian 25.56 cHD associated PAH  none 37
16 25 F c 24.85 iPAH Sildenafil 1.2
17 73 F c 25.68 iPAH Sildenafil 6.8
18 61 F c 23.4 iPAH epoprostenol 7.7
Note: *in addition to sitaxsentan.
Abbreviations: PAH, pulmonary arterial hypertension; iPAH, idiopathic pulmonary arterial hypertension; cTD, collagen tissue disease; cHD, congenital heart disease; 
c, caucasian; H, Hispanic; BMi, body mass index.
Table 2 Serum aminotransferase concentrations in transitioned 
patients
Pre  
transition
1 month post 
transition
1 year post 
transition
AST (mU/mL) 19 ± 8 31 ± 35* 26 ± 19
ALT (mU/mL) 16 ± 7 23 ± 23 24 ± 18
Notes: *Patient 15 AST increased to 151 mU/mL at 1 month then decreased 
to 19 mU/mL in 1 week without any intervention. This patient was subsequently 
switched to bosentan (3 months post transition) for worsening right heart failure 
and died 5 months after transition. normal laboratory values: AST = 10–42 mU/mL; 
ALT = 10–60 mU/mL.
Abbreviations: AST, aspartate aminotransferase; ALT, alanine transaminase.
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Figure 1 Six-minute walk distance at transition and follow-up in PAH patients.
Abbreviation: PAH, pulmonary hypertension.
determine whether our findings would differ in patients with 
different PAH etiologies. There was no significant difference 
between the 2 groups at PreT, 1Mth, and 1Yr in 6MWD 
(P = 0.42, 0.34, 0.27 respectively), BNP levels (P = 0.63, 
0.90, 0.55 respectively), oxygen saturation (P = 0.35, 0.47, 
0.06 respectively), and BDS (0.55, 0.45, 0.39 respectively). 
Peripheral edema was present in 7/18 patients at PreT, 
8/16 patients at 1Mth, and in 6/13 patients at 1yr (Figure 3). At 
1Mth, the diuretic dose was increased in 2 of the 16 patients 
(patients 4 and 18). At 1Yr, a second diuretic was added for 
patient 4. Proportions of patients with edema over these 3 
time points did not change significantly (P = 0.803).
Oxygen saturation was not different at 1Mth compared with 
PreT (P = 0.49). Oxygen requirements remained unchanged 
except for 1 patient who was on room air PreT and was started 
on 2 L oxygen at 1Mth and remained on 2 L at 1Yr. 1Yr data 
were available for 13 patients and oxygen saturation slightly 
improved compared with PreT (P = 0.06).
 Over 3 points (PreT, 1Mth, and 1Yr), there was no signifi-
cant change in WHO function class (P = 0.672) (Figure 4).
Discussion
In this single-center retrospective study switching from sitax-
sentan to ambrisentan was safe and efficacy was maintained. 
At the end of the open label extension phase of STRIDE 
studies, we switched all of the patients then enrolled to 
ambrisentan. In the open label extension phase, addition of 
PAH therapies was allowed. Prior to transitioning, 3 patients 
enrolled in this extension phase had died. Our data suggest 
that switching from a selective ETRA to another selective 
ETRA may be reasonable and safe. However, 3 patients in 
our cohort developed disease worsening and 2 patients died Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Figure 3 Borg dyspnea score at transition and follow-up in PAH patients. Data 
presented as mean ± standard deviation.
Abbreviations: PAH, pulmonary hypertension; SD, standard deviation.
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Figure 4 Presence of peripheral edema at transition and follow-up. Data presented 
as percentage (%). One patient had undergone lung transplantation, 1 patient had 
relocated, and 2 patients had died at 1 year follow-up.
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Figure 5 WHO Functional class at transition and at follow-up in transitioned 
patients. Data presented as percentage (%).
after this change, suggesting that individual responses to 
selective ET receptor antagonists may vary.
Ambrisentan and sitaxsentan are both ETA-selective 
antagonists. Based on in vitro competitive receptor 
binding assay, ambrisentan has a 77-fold affinity for ETA 
compared with ETB receptors.3 On the other hand, sitaxsen-
tan has a ∼6500-fold affinity for ETA compared with ETB 
receptors.4,5 Activation of the ETA receptor on smooth muscle 
cells causes sustained vasoconstriction and proliferation of 
these cells. However, activation of ETB on endothelial cells 
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Figure 2 BnP levels at transition and follow-up in PAH patients. Data presented as 
mean ± standard error.
Abbreviations: BnP, brain naturetic peptide; PAH, pulmonary hypertension.
induces clearance of ET-1 from the circulation and mediates 
vasodilation through the activation of NO and prostacyclin. 
This selectivity of ETA receptor blockages has been proposed 
to prevent the deleterious effects of ETA, while allowing 
the favorable effects of ETB.2 However, this difference in 
selectively has not translated into substantial differences in 
clinical efficacy, as shown by the published clinical studies.6–10 
Our data show that the walk distance was maintained for up 
to 1 year after the switch in the ETRA. This suggests that 
selective ETRA can be used interchangeably as required by 
the clinical necessity. However, we caution against using this 
data for the dual receptor ETRA, because we switched our 
patients to a selective ETRA, ambrisentan, in our cohort.
Both ambrisentan and sitaxsentan have a long half-life and 
require once daily dosing.7,11,12 Ambrisentan is a propanoic 
acid-based compound that is metabolized   predominately by 
glucuronidation and transported via the bile. Sitaxsentan is 
derived from amidothiophenesulponamides by a series of 
chemical modifications. It is metabolized by the CYP2CP and 
CYP3A4 with 50% to 60% of the dose excreted in the urine 
and the remaining in feces. The incidence of liver function Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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test abnormalities is similar between the two drugs (3% with 
both ambrisentan and sitaxsentan).7,11,13
Transitioning from one ETRA to another ETRA may be 
required in different clinical situations. This may be because 
of side-effects, liver function abnormalities, or availability of 
the drug. McGoon et al have previously shown that patients 
who discontinued bosentan due to liver function test abnor-
malities tolerated ambrisentan and this change resulted in 
improvement in walk distance.14 We have previously shown 
that carefully selected patients can be safely transitioned 
from intravenous prostacyclin to oral agents.15 Our data was 
obtained from patients with normal liver function who were 
switched to ambrisentan when the sitaxsentan did not gain 
FDA approval in US. We included patients who died, were 
lost to follow-up, or underwent lung transplantation. We did 
not exclude any patient to prevent an introduction of bias in 
data collection. Patient 15 in our cohort developed transient 
elevation in transaminase, which resolved spontaneously 
without any medical intervention. This patient had a con-
genital heart defect (ventricular septal defect), Eisenmenger 
physiology, and Down syndrome. This patient was not on 
any additional PAH therapy due to significant underlying 
medical conditions and parents’ request. This patient did not 
develop increased edema at 1Mth and the parents felt that the 
breathing was unchanged. However, this patient developed an 
intolerable cough and 3 months post transition the walk dis-
tance had significantly deteriorated and therefore the patient 
was switched to bosentan and subsequently died 5 months 
post transition. It is conceivable that the clinical condition 
may have deteriorated when this patient was switched from 
sitaxsentan to ambrisentan. On the other hand, this patient 
was 45 years of age at the time of transition and had been 
diagnosed with PAH for the previous 37 years. Possibly this 
patient was at the end of the disease spectrum.
Peripheral edema is considered to be a class side-effect 
of ETRAs,16 with a greater percentage of older patients 
(.65 years) experiencing higher rates of peripheral edema.16 
Some ETRAs were thought to be associated with more 
peripheral edema than others. However, our data suggest 
that at least in the selective ETRAs there was no significant 
worsening of peripheral edema. None of the patients required 
intravenous diuresis or hospitalization for worsening edema. 
One patient, however, who was already in the hospital at the 
time of study closure, developed worsening right heart failure 
and subsequently died. This could have been related to the 
progression of disease or, on the other hand, may have been 
related to worsening right heart failure as a consequence of 
increased fluid retention caused by a switch in the ETRA. 
Therefore, switching ETRA in patients with marginal clinical 
status should be undertaken cautiously. We do not recom-
mend switching between ETRAs without a compelling 
reason such as when side-effects must be mitigated. Hence, 
such switches should be undertaken only when they confer 
a greater clinical benefit to the patient.
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